NLS Business article

A new study co-authored by Jonathan Ilicki, Life Science Strategy Lead at the Swedish venture capital firm Industrifonden, finds that investment and business-development professionals often misjudge rare-disease assets, underestimating launch performance and misreading when the assets are most commonly acquired.

The ongoing struggle in the Nordic countries to keep prescription drug prices affordable without shutting out innovative, more expensive therapies continues to frustrate pharmaceutical companies as the introduction of new drugs to the region slows.

Stockholm’s life science ecosystem has long shone brightly for its scientific excellence. Now, the region is tackling how to turn its world-class research, strong infrastructure, and an industrial legacy into sustained global competitiveness.

NordicRWE has established offices in Sweden and Denmark alongside its Oslo base, aiming to make it easier to run health data studies across the whole Nordic region – particularly in cancer, where precision medicine is splitting patients into ever-smaller subgroups.

Episurf Medical has concluded the strategic review of its medtech operations and will now pursue an orderly wind-down of that business, accelerating its transformation into a pure-play Nordic property company.

NLS asked the CEO and co-founder of Pixelgen about entrepreneurship in Sweden, the company's global commercialization strategy and the most exciting clinical applications of the company's Proxiome kit.